Kura Oncology (KURA) director exercises 10,000 options for shares

Rhea-AI Filing Summary

Kura Oncology director Thomas Malley exercised stock options to acquire 10,000 shares of common stock at $3.12 per share. The options were fully vested, and this exercise used his remaining options from that grant, leaving no options from it outstanding. After the transaction, he directly holds 10,000 common shares and indirectly holds 139,557 common shares through Mossrock Capital, LLC, where he serves as President with sole voting and investment power over those shares.

Insider Trade Summary

10,000 shares exercised/converted

Mixed 3 txns

Insider Malley Thomas

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$3.12	$31K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 10,000 shares (Direct); Common Stock — 139,557 shares (Indirect, By Mossrock Capital, LLC)

Footnotes (1)

1. Represents stock options exercised. Mr. Malley serves as President of Mossrock Capital, LLC and has sole voting and investment power over these shares. This option is fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malley Thomas

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		M(1)		10,000	A	$3.12	10,000	D
Common Stock								139,557	I	By Mossrock Capital, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.12	03/18/2026		M(1)		10,000		(3)	05/11/2026	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. Represents stock options exercised.

2. Mr. Malley serves as President of Mossrock Capital, LLC and has sole voting and investment power over these shares.

3. This option is fully vested.

	/s/ Teresa Bair, Attorney-in-fact for Thomas Malley	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kura Oncology (KURA) director Thomas Malley report?

Director Thomas Malley reported exercising stock options to acquire 10,000 Kura Oncology common shares at a conversion price of $3.12 per share. This derivative exercise converted a previously held option grant into directly owned common stock.

How many Kura Oncology shares does Thomas Malley hold after this Form 4 filing?

After the reported transactions, Thomas Malley directly owns 10,000 Kura Oncology common shares. He also indirectly holds 139,557 common shares through Mossrock Capital, LLC, where he has sole voting and investment power over those indirectly held shares.

Was the Kura Oncology Form 4 transaction a stock purchase or an option exercise?

The Form 4 transaction reflects an option exercise, not an open-market stock purchase. Malley exercised fully vested stock options with a $3.12 exercise price to receive 10,000 Kura Oncology common shares, classified as a derivative exercise/conversion under transaction code M.

Does Thomas Malley still hold any Kura Oncology stock options after this exercise?

For the option grant reported, the filing shows zero derivative securities remaining after exercising 10,000 options. This indicates the particular option award referenced in the Form 4 has been fully exercised, with no remaining options from that grant outstanding.

How are Thomas Malley’s indirect Kura Oncology holdings structured?

Malley’s indirect holdings consist of 139,557 Kura Oncology common shares held by Mossrock Capital, LLC. He serves as President of Mossrock Capital and has sole voting and investment power over these shares, so they are reported as indirectly owned on the Form 4.

What does transaction code M mean in the Kura Oncology Form 4?

Transaction code M on the Form 4 indicates the exercise or conversion of a derivative security. In this case, it refers to Malley’s exercise of stock options with a $3.12 exercise price to receive 10,000 Kura Oncology common shares on March 18, 2026.